Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease

Summary

This study evaluates the use of Brimonidine tartrate nanoemulsion eye drop solution in the treatment of ocular Graft Verses Host Disease (oGVHD). Two thirds of participants will receive Brimonidine and one third will receive ophthalmic buffered saline (placebo).

Timeline

Start

2018-12-23

Primary completion

2020-04-30

Completion

2020-04-30

Outcome

Outcome not reported

Stopped: “Primary endpoint was not met.”

Drugs

Indications